Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
8.49
+0.16 (1.92%)
At close: Apr 2, 2026, 4:00 PM EDT
8.48
-0.01 (-0.12%)
After-hours: Apr 2, 2026, 7:33 PM EDT
Ocular Therapeutix Employees
Ocular Therapeutix had 325 employees as of December 31, 2025. The number of employees increased by 51 or 18.61% compared to the previous year.
Employees
325
Change (1Y)
51
Growth (1Y)
18.61%
Revenue / Employee
$159,849
Profits / Employee
-$818,274
Market Cap
1.85B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 325 | 51 | 18.61% |
| Dec 31, 2024 | 274 | 7 | 2.62% |
| Dec 31, 2023 | 267 | -7 | -2.55% |
| Dec 31, 2022 | 274 | 46 | 20.18% |
| Dec 31, 2021 | 228 | 47 | 25.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Galapagos NV | 558 |
| Vericel | 398 |
| Zymeworks | 264 |
| Viridian Therapeutics | 252 |
| Capricor Therapeutics | 231 |
| Stoke Therapeutics | 170 |
| Pharvaris | 118 |
| Mesoblast | 81 |
OCUL News
- 3 days ago - Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - GlobeNewsWire
- 14 days ago - EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
- 25 days ago - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript - Seeking Alpha
- 6 weeks ago - Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 6 weeks ago - Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript - Seeking Alpha
- 6 weeks ago - Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial - Reuters
- 7 weeks ago - Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - GlobeNewsWire